Identification of Disulfidptosis-related Clusters and Construction of a Disulfidptosis-related Gene Prognostic Signature in Triple-negative Breast Cancer

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jul 12

PMID 38994057

Authors

Jie Wu

Yan Cai

Gaiping Zhao

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to explore disulfidptosis-related clusters of triple-negative breast cancer (TNBC) and build a reliable disulfidptosis-related gene signature for forecasting TNBC prognosis.

Methods: The disulfidptosis-related clusters of TNBC were identified based on public datasets, and a comparative analysis was conducted to assess their differences in the overall survival (OS) and immune cell infiltration. Morever, the differentially expressed genes (DEGs) between clusters were recognized. Then, the prognostic DEGs were then chosen. A prognostic signature was constructed by the prognostic DEGs, followed by nomogram construction, drug sensitivity, immune correlation, immunotherapy response prediction, and cluster association analyses.

Results: Two disulfidptosis-related clusters of TNBC were identified, which had different OS and macrophage infiltration. Moreover, 235 DEGs were identified between two clusters. A prognostic signature was then constructed by five prognostic DEGs including HLA-DQA2, CCL13, GBP1, LAMP3, and SLC7A11. This signature was highly valuable in predicting prognosis. A nomogram was built by risk score and AJCC stage, which could forecast OS accurately. Moreover, patients with high-risk scores exhibited greater sensitivity to chemotherapy drugs such as lapatinib and had a lower immunotherapy response.

Conclusions: Two TNBC clusters linked to disulfidptosis were identified, with different OS and immune cell infiltration. Moreover, a five-disulfidptosis-related gene signature may be a powerful prognostic biomarker for TNBC.

References

Xiao B, Liu L, Li A, Xiang C, Wang P, Li H . Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma. Front Oncol. 2021; 10:607622. PMC: 7771722. DOI: 10.3389/fonc.2020.607622. View

Chen C, Shen M, Liao H, Guo Q, Fu H, Yu J . A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer. J Nanobiotechnology. 2021; 19(1):55. PMC: 7905927. DOI: 10.1186/s12951-021-00800-z. View

Rizvi A, Karaesmen E, Morgan M, Preus L, Wang J, Sovic M . gwasurvivr: an R package for genome-wide survival analysis. Bioinformatics. 2018; 35(11):1968-1970. PMC: 7963072. DOI: 10.1093/bioinformatics/bty920. View

Rizzo A, Ricci A, Lanotte L, Lombardi L, Di Federico A, Brandi G . Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs. 2021; 31(6):557-565. DOI: 10.1080/13543784.2022.2009456. View

Zhang S, Tong Y, Zhang X, Zhang Y, Xu X, Xiao A . A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. J Cancer. 2019; 10(24):5944-5954. PMC: 6856574. DOI: 10.7150/jca.35785. View

Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A . Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc. 2019; 14(2):482-517. PMC: 6607905. DOI: 10.1038/s41596-018-0103-9. View

Liu C, Hu M, Hsu C, Huang C, Wang D, Tsai W . Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget. 2016; 7(8):9135-49. PMC: 4891031. DOI: 10.18632/oncotarget.7035. View

Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G . Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022; 31(6):495-498. DOI: 10.1080/13543784.2022.2042252. View

Chen B, Khodadoust M, Liu C, Newman A, Alizadeh A . Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018; 1711:243-259. PMC: 5895181. DOI: 10.1007/978-1-4939-7493-1_12. View

10.

Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W . Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg. 2022; 107:106936. DOI: 10.1016/j.ijsu.2022.106936. View

11.

Hu D, Zhou M, Zhu X . Deciphering Immune-Associated Genes to Predict Survival in Clear Cell Renal Cell Cancer. Biomed Res Int. 2019; 2019:2506843. PMC: 6925759. DOI: 10.1155/2019/2506843. View

12.

Zheng P, Zhou C, Ding Y, Duan S . Disulfidptosis: a new target for metabolic cancer therapy. J Exp Clin Cancer Res. 2023; 42(1):103. PMC: 10134647. DOI: 10.1186/s13046-023-02675-4. View

13.

Franzen B, Alexeyenko A, Kamali-Moghaddam M, Hatschek T, Kanter L, Ramqvist T . Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. Mol Oncol. 2018; 13(2):376-391. PMC: 6360506. DOI: 10.1002/1878-0261.12410. View

14.

Disis M, Stanton S . Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book. 2015; :e25-30. DOI: 10.14694/EdBook_AM.2015.35.e25. View

15.

Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y . CCL13 and human diseases. Front Immunol. 2023; 14:1176639. PMC: 10154514. DOI: 10.3389/fimmu.2023.1176639. View

16.

Quintero M, Adamoski D, Menezes Dos Reis L, Rodrigues Ascencao C, Sousa de Oliveira K, Almeida Goncalves K . Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. BMC Cancer. 2017; 17(1):727. PMC: 5688804. DOI: 10.1186/s12885-017-3726-2. View

17.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

18.

Zerdan M, Ghorayeb T, Saliba F, Allam S, Zerdan M, Yaghi M . Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers (Basel). 2022; 14(5). PMC: 8909187. DOI: 10.3390/cancers14051253. View

19.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

20.

Zhao S, Wang L, Ding W, Ye B, Cheng C, Shao J . Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework. Front Endocrinol (Lausanne). 2023; 14:1180404. PMC: 10154596. DOI: 10.3389/fendo.2023.1180404. View